Trials / Completed
CompletedNCT00983801
Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
A Phase II Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer Previously Treated With Fluoropyrimidine-based Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- R-Pharm · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine whether ixabepilone is effective in the treatment of unresectable or metastatic gastric cancer in Asian participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ixabepilone | Vial, Injection, Intravenous (IV), 40 mg/m\^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2009-09-24
- Last updated
- 2020-10-28
- Results posted
- 2012-09-19
Locations
9 sites across 5 countries: Hong Kong, Japan, Singapore, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT00983801. Inclusion in this directory is not an endorsement.